On This Day in Health: June 19, 2025
On June 19, 2025, Cycle Pharmaceuticals announced from Boston and Cambridge, England, that Harliku, its nitisinone tablets, had received U.S. approval for adults with alkaptonuria. The announcement brought public attention to the first FDA-approved treatment for this rare inherited metabolic disorder. Its specific authorized purpose was reducing homogentisic acid in patients' urine. The distinction between announcement and approval matters: the FDA's approval letter was electronically signed on June 10, while Cycle released the news on June 19. The company planned a July launch, so the anniversary marks the public announcement of the milestone rather than the first day patients could obtain the product.
Alkaptonuria disrupts the body's breakdown of certain amino acids, allowing homogentisic acid to accumulate. Urine can darken after exposure to air, while a related pigment can build up in connective tissue, a process known as ochronosis. Over time, patients may develop painful joint damage and problems affecting other organs, including the heart and kidneys. The disease's rarity can make recognition and research difficult, even when its effects become severe. Nitisinone works earlier in the metabolic pathway to reduce production of the substance that accumulates. It had an established medical history in another inherited disorder, hereditary tyrosinemia type 1, before this U.S. alkaptonuria indication.
The research behind the announcement included a three-year randomized study of 40 adults conducted through the National Human Genome Research Institute at the National Institutes of Health. Investigators including Wendy Introne and colleagues documented a large, sustained reduction in homogentisic acid with nitisinone. The original trial did not demonstrate a statistically significant improvement in its primary clinical measure, movement at the more affected hip. Later analyses examined patients' reported symptoms and physical functioning. These different findings required careful interpretation. Lowering a biochemical marker was a concrete result, but it did not mean that damaged joints had been restored or that every clinical complication had been prevented.
The new indication offered a treatment directed at the disease's underlying chemical buildup, alongside the continuing need for broader medical care. Nitisinone could also raise tyrosine levels, creating a need for monitoring and attention to eye complications and other adverse effects. Approval therefore represented a new option rather than a risk-free cure. Its importance extended beyond a product announcement: a disease long associated with progressive tissue damage now had an authorized U.S. medicine targeting a measurable part of its biology. The June 19 news connected decades of metabolic research, a small patient population and a practical treatment pathway, while preserving the difference between biochemical improvement, symptom relief and proof of lasting protection from disability.
Alkaptonuria is an inherited metabolic disorder associated with homogentisic acid accumulation. Darkening urine can be an early clue, while pigment deposition and joint disease may develop over many years.
Nitisinone reduces production of homogentisic acid by blocking an earlier step in its metabolic pathway. It does not repair the inherited gene change or directly rebuild damaged cartilage.
Cycle's public announcement was dated June 19, 2025. The FDA approval letter's signature was dated June 10, and commercial launch followed in July; these dates describe different events.
The approved indication concerned reducing urinary homogentisic acid in adults. The original 40-person trial's biochemical findings should be distinguished from its lack of a significant result on the primary hip-movement measure.
The announcement marked the arrival of a first FDA-approved medicine for a very small disease community. It also illustrated the contribution of sustained public research to treatment development for rare disorders.
Long-term care still involved monitoring and management of existing complications. The milestone supports a precise claim about a new treatment pathway, rather than a claim that alkaptonuria had been cured.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.